- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
BGB-16673 Displays a High ORR and Tolerability in Waldenström Macroglobulinemia
June 19th 2025, 8:57pm
European Hematology Association Congress
BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.
Dr Pan on the Real-World Utilization of Tarlatamab in Patients With SCLC
June 19th 2025, 8:42pm
Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.
GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting
June 19th 2025, 5:35pm
Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.
Hematologists Highlight Notable Insights From the 2025 EHA Congress
June 18th 2025, 1:00pm
European Hematology Association Congress
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS
June 17th 2025, 9:11pm
European Hematology Association Congress
Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
June 17th 2025, 5:09pm
European Hematology Association Congress
Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
June 17th 2025, 4:40pm
European Hematology Association Congress
Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
June 16th 2025, 8:20pm
European Hematology Association Congress
PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
June 16th 2025, 4:46pm
A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
June 16th 2025, 4:38pm
European Hematology Association Congress
Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
June 16th 2025, 3:18pm
European Hematology Association Congress
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.
Epcoritamab Plus R-ICE Yields High CR Rates and Improves Transplant Eligibility in R/R DLBCL
June 15th 2025, 5:47pm
European Hematology Association Congress
The majority of transplant-eligible patients with relapsed/refractory DLBCL completed treatment with epcoritamab plus R-ICE and proceeded to ASCT.
Fixed-Duration Epcoritamab Plus Pola-R-CHP Demonstrates Durable Efficacy in First-Line DLBCL
June 15th 2025, 5:38pm
European Hematology Association Congress
Further exploration of epcoritamab plus pola-R-CHP in first-line diffuse large B-cell lymphoma is warranted.
Consolidation Blinatumomab Improves Efficacy Vs Chemo in Newly Diagnosed BCR::ABL1– B ALL
June 15th 2025, 2:20pm
European Hematology Association Congress
The E1910 trial results showed improved OS and RFS with blinatumomab vs chemotherapy in patients with newly diagnosed BCR::ABL1-negative B ALL.
BGB-16673 Is Safe, Elicits Nearly 85% ORR in Relapsed/Refractory CLL/SLL
June 15th 2025, 2:04pm
European Hematology Association Congress
BGB-16673 showed a favorable safety profile and promising antitumor activity in relapsed/refractory CLL/SLL, with responses seen across baseline mutations.
Dr Scarfò on Updated Safety Data With BGB-16673 in Relapsed/Refractory CLL/SLL
June 15th 2025, 1:15pm
European Hematology Association Congress
Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma
June 15th 2025, 12:50pm
European Hematology Association Congress
Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.
Early Daratumumab in Patients With Myeloma Experiencing MRD Relapse Delays Clinical Progression
June 15th 2025, 1:21am
European Hematology Association Congress
PREDATOR-MRD data can serve as proof of concept for larger trials with novel MRD assessment techniques.
Anito-Cel Drives Durable Responses in R/R Multiple Myeloma
June 14th 2025, 7:53pm
European Hematology Association Congress
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
IRAKLIA Data Support Subcutaneous Isatuximab as a SOC Administration Approach in Myeloma
June 14th 2025, 7:43pm
European Hematology Association Congress
The IRAKLIA study examined the use of an innovative on-body injector for isatuximab administration in multiple myeloma.